ZTSZoetis
Price
-49%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growth steady, the market undecided.
Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Zoetis (ZTS) reported revenue of $2.47B in Q2 2026 (quarter ended Jun 30, 2026), down 0.2% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $691M (28% of revenue). For the full year FY2025, revenue was $9.47B (+2.3% year on year) and net income $2.67B. Its largest product in Q2 2026 was Dermatology at $398M, 17.5% of the disclosed total, just ahead of Cattle at 17.1%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026Zoetis Declares Fourth Quarter 2026 Dividend.Regulation FD disclosure · press release
- Aug 6, 2026Zoetis Announces Second Quarter 2026 Results.Earnings release · press release
- Aug 6, 2026Appointment of James Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer On August 6, 2026, Zoetis Inc. (the “Company”) announced that James Saccaro has been appointed as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $2.28BThe company’s own SEC segment disclosure.
- Dermatology$398.0M17%
- Cattle$390.0M17%
- Anti Infective Products$244.0M11%
- Livestock$222.0M10%
- Pain Sedation$217.0M10%
- Other Pharmaceuticals$168.0M7%
- Other (8)$637.0M28%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry